These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34273351)

  • 21. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
    Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
    Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD22 antigen: biosynthesis, glycosylation and surface expression of a B lymphocyte protein involved in B cell activation and adhesion.
    Schwartz-Albiez R; Dörken B; Monner DA; Moldenhauer G
    Int Immunol; 1991 Jul; 3(7):623-33. PubMed ID: 1716973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance.
    Nitschke L
    Glycobiology; 2014 Sep; 24(9):807-17. PubMed ID: 25002414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
    Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
    Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
    Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
    Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-Linked Glycosylation Regulates CD22 Organization and Function.
    Wasim L; Buhari FHM; Yoganathan M; Sicard T; Ereño-Orbea J; Julien JP; Treanor B
    Front Immunol; 2019; 10():699. PubMed ID: 31019513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22.
    Chen WC; Sigal DS; Saven A; Paulson JC
    Leuk Lymphoma; 2012 Feb; 53(2):208-10. PubMed ID: 21756025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking.
    Han S; Collins BE; Bengtson P; Paulson JC
    Nat Chem Biol; 2005 Jul; 1(2):93-7. PubMed ID: 16408005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD22: an inhibitory enigma.
    Walker JA; Smith KG
    Immunology; 2008 Mar; 123(3):314-25. PubMed ID: 18067554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
    Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
    Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo.
    Haas KM; Sen S; Sanford IG; Miller AS; Poe JC; Tedder TF
    J Immunol; 2006 Sep; 177(5):3063-73. PubMed ID: 16920943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation.
    Courtney AH; Puffer EB; Pontrello JK; Yang ZQ; Kiessling LL
    Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2500-5. PubMed ID: 19202057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.
    Matsubara N; Imamura A; Yonemizu T; Akatsu C; Yang H; Ueki A; Watanabe N; Abdu-Allah H; Numoto N; Takematsu H; Kitazume S; Tedder TF; Marth JD; Ito N; Ando H; Ishida H; Kiso M; Tsubata T
    Front Immunol; 2018; 9():820. PubMed ID: 29725338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
    Liu S; Zhang X; Dai H; Cui W; Yin J; Li Z; Yang X; Yang C; Xue S; Qiu H; Miao M; Chen S; Jin Z; Fu C; Li C; Sun A; Han Y; Wang Y; Yu L; Wu D; Cui Q; Tang X
    Blood Cancer J; 2023 Apr; 13(1):60. PubMed ID: 37095120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
    Sullivan-Chang L; O'Donnell RT; Tuscano JM
    BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.
    O'Donnell RT; Ma Y; McKnight HC; Pearson D; Tuscano JM
    Cancer Immunol Immunother; 2009 Dec; 58(12):2051-8. PubMed ID: 19437017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.
    Becerril-Rico J; Delgado-Montes YA; Ortiz-Sánchez E
    Leuk Lymphoma; 2023; 64(11):1822-1831. PubMed ID: 37548560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CD33.
    Sgroi D; Nocks A; Stamenkovic I
    J Biol Chem; 1996 Aug; 271(31):18803-9. PubMed ID: 8702538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity.
    Zeng W; Zhang Q; Zhu Y; Ou R; Peng L; Wang B; Shen H; Liu Z; Lu L; Zhang P; Liu S
    Cancer Invest; 2022 Mar; 40(3):282-292. PubMed ID: 34797742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Localization of the putative sialic acid-binding site on the immunoglobulin superfamily cell-surface molecule CD22.
    van der Merwe PA; Crocker PR; Vinson M; Barclay AN; Schauer R; Kelm S
    J Biol Chem; 1996 Apr; 271(16):9273-80. PubMed ID: 8621588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.